KA-3123-LD38
/ KYinno, Escugen Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
KA-3123-LD38: a novel bispecific antibody-drug conjugate (ADC) targeting EGFR and B7H3 with a DNA topoisomerase I inhibitor payload
(AACR 2025)
- "Ongoing toxicity studies suggest that KA-3123-LD38 has a favorable safety profile, with low toxicity observed. These promising results highlight KA-3123-LD38 as a potentially powerful treatment for a broad range of solid tumors."
Colorectal Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • CD276 • EGFR
1 to 1
Of
1
Go to page
1